Dr Shilpa Gupta, a medical oncologist at the Cleveland Clinic, provided insights into the long-term outcomes of patients enrolled in the EV-103 study. This study evaluated the combination of enfortumab vedotin and pembrolizumab as a first-line treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. The outcomes up to 4 years of follow-up were presented, shedding light on the efficacy and durability of this treatment approach.
With the educational support of:
